MYCELEX-7 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MYCELEX-7 COMBINATION PACK (MYCELEX-7 COMBINATION PACK).
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
| Metabolism | Clotrimazole is metabolized in the liver primarily via oxidation and glucuronidation, involving CYP3A4. Miconazole is metabolized in the liver via oxidative pathways, primarily by CYP3A4 and CYP2C9. |
| Excretion | Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible. |
| Half-life | Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects. |
| Protein binding | Clotrimazole is 97-99% protein-bound (primarily to albumin). |
| Volume of Distribution | Volume of distribution is not well-characterized due to minimal systemic absorption; estimated Vd is approximately 0.1 L/kg after topical application, reflecting limited distribution. |
| Bioavailability | Bioavailability: Vaginal tablet—3-10% absorbed systemically; topical cream/solution—<0.5% absorbed; negligible systemic exposure after topical use. |
| Onset of Action | Onset: Vaginal tablet—relief of symptoms typically begins within 24 hours; topical cream or solution—local symptomatic improvement within 2-4 days. |
| Duration of Action | Duration: Vaginal tablet—sustained release over 24-72 hours; topical cream/solution—effects last for the duration of application, typically 7 days for candidal infections. |
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
| Dosage form | CREAM, TABLET |
| Renal impairment | No dose adjustment required for renal impairment. Systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment. Systemic absorption is minimal. |
| Pediatric use | Not recommended for children under 12 years of age. For children 12 years and older, same as adult dosing. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. Consider potential for decreased renal/hepatic function but no adjustment necessary due to minimal systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MYCELEX-7 COMBINATION PACK (MYCELEX-7 COMBINATION PACK).
| Breastfeeding | Clotrimazole is minimally absorbed systemically after vaginal application; therefore, excretion into breast milk is negligible. The milk-to-plasma ratio (M/P) is not clinically relevant because plasma concentrations are very low. It is considered compatible with breastfeeding. No adverse effects in infants have been reported. |
| Teratogenic Risk | Clotrimazole, the active ingredient in MYCELEX-7 COMBINATION PACK, is classified as FDA Pregnancy Category C. Systemic absorption after vaginal application is minimal (approximately 3-10%). Animal studies with high subcutaneous doses have shown embryotoxicity; however, no teratogenic effects have been observed in humans with standard topical use. There is no evidence of fetal risk in the first trimester based on large epidemiological studies. Second and third trimesters: no known risk when used as directed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component (clotrimazole, miconazole nitrate, or other imidazoles) or to polyethylene glycol and other excipients."]
| Precautions | ["For intravaginal use only; not for ophthalmic or oral use.","Discontinue if irritation or hypersensitivity occurs.","Use during pregnancy only if clearly needed (pregnancy category C).","Instruct patient to consult physician if symptoms persist beyond 7 days or recur within 2 months.","Possible interaction with warfarin (miconazole component may enhance anticoagulant effect)."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required beyond standard prenatal care. For recurrent symptoms or treatment failure, confirm diagnosis and rule out other pathogens. Fetal monitoring is not indicated. |
| Fertility Effects | No known adverse effects on fertility in women. Animal studies do not indicate impaired fertility. Clotrimazole is used for vulvovaginal candidiasis and does not impact ovarian function or conception. |